Korro Bio, Inc. Stock-Based Compensation
Korro Bio, Inc. (KRRO) reported Stock-Based Compensation of $2.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- Korro Bio, Inc. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $2.70M, a 35.29% increase year-over-year.
- Korro Bio, Inc. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $2.73M, a 55.08% increase year-over-year.
- Korro Bio, Inc. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $2.07M, a 52.62% increase year-over-year.
- Korro Bio, Inc. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $1.82M, a 43.36% increase year-over-year.
- Korro Bio, Inc. share-based payment arrangement, expense for fiscal 2025 was $7.66M, a 71.56% increase from fiscal 2024.
- Korro Bio, Inc. share-based payment arrangement, expense for fiscal 2024 was $4.46M, a 87.40% increase from fiscal 2023.
- Korro Bio, Inc. share-based payment arrangement, expense for fiscal 2023 was $2.38M, a 108.86% increase from fiscal 2022.
- Korro Bio, Inc. share-based payment arrangement, expense for fiscal 2022 was $1.14M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.70M 10-Q · filed 2026-08-06 | $5.43M 10-Q · filed 2026-08-06 | $7.50M derived: sum of 3 quarters · filed 2026-08-06 | $9.33M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $2.73M 10-Q · filed 2026-05-07 | $4.80M derived: sum of 2 quarters · filed 2026-05-07 | $6.63M derived: sum of 3 quarters · filed 2026-05-07 | $8.63M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.90M derived: sum of 2 quarters · filed 2026-03-12 | $5.89M derived: sum of 3 quarters · filed 2026-08-06 | $7.66M 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $1.82M 10-Q · filed 2025-11-12 | $3.82M derived: sum of 2 quarters · filed 2026-08-06 | $5.58M 10-Q · filed 2025-11-12 | $6.94M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $2.00M 10-Q · filed 2026-08-06 | $3.76M 10-Q · filed 2026-08-06 | $5.12M derived: sum of 3 quarters · filed 2026-08-06 | $6.39M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $1.76M 10-Q · filed 2026-05-07 | $3.12M derived: sum of 2 quarters · filed 2026-05-07 | $4.39M derived: sum of 3 quarters · filed 2026-05-07 | $5.36M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.63M derived: sum of 2 quarters · filed 2026-03-12 | $3.60M derived: sum of 3 quarters · filed 2026-03-12 | $4.46M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $1.27M 10-Q · filed 2025-11-12 | $2.24M derived: sum of 2 quarters · filed 2025-11-12 | $3.10M 10-Q · filed 2025-11-12 | $4.33M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $967.00K 10-Q · filed 2025-08-12 | $1.83M 10-Q · filed 2025-08-12 | $3.06M derived: sum of 3 quarters · filed 2025-08-12 | $3.46M derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | $865.00K 10-Q · filed 2025-05-07 | $2.09M derived: sum of 2 quarters · filed 2025-05-07 | $2.50M derived: sum of 3 quarters · filed 2025-05-07 | $2.90M derived: sum of 4 quarters · filed 2025-05-07 | |||
| 2023-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.63M derived: sum of 2 quarters · filed 2025-03-18 | $2.03M derived: sum of 3 quarters · filed 2025-03-18 | $2.38M 10-K · filed 2025-03-18 | |||
| 2023-09-30 | $404.00K 10-Q · filed 2024-11-12 | $2.92M 10-Q · filed 2023-11-02 | $805.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.15M 10-Q · filed 2024-11-12 | $9.25M 10-Q · filed 2023-11-02 | -$13.13M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $401.00K 10-Q · filed 2024-08-13 | $2.90M 10-Q · filed 2023-08-10 | $750.00K 10-Q · filed 2024-08-13 | $6.33M 10-Q · filed 2023-08-10 | -$13.54M derived: sum of 3 quarters · filed 2024-08-13 | -$7.94M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $349.00K 10-Q · filed 2024-05-14 | $3.43M 10-Q · filed 2023-05-12 | -$13.94M derived: sum of 2 quarters · filed 2024-05-14 | -$8.34M derived: sum of 3 quarters · filed 2024-05-14 | -$3.78M derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | -$14.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$8.69M derived: sum of 2 quarters · filed 2024-03-26 | -$4.13M derived: sum of 3 quarters · filed 2024-03-26 | $1.14M 10-K · filed 2024-03-26 | |||
| 2022-09-30 | $5.59M 10-Q · filed 2023-11-02 | $10.16M derived: sum of 2 quarters · filed 2023-11-02 | $15.43M 10-Q · filed 2023-11-02 | ||||
| 2022-06-30 | $4.56M 10-Q · filed 2023-08-10 | $9.83M 10-Q · filed 2023-08-10 | |||||
| 2022-03-31 | $5.27M 10-Q · filed 2023-05-12 | ||||||
| 2021-09-30 | $5.89M 10-Q · filed 2022-11-08 | $11.97M derived: sum of 2 quarters · filed 2022-11-08 | $16.59M 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | $6.09M 10-Q · filed 2022-08-09 | $10.70M 10-Q · filed 2022-08-09 | |||||
| 2021-03-31 | $4.61M 10-Q · filed 2022-05-04 | ||||||
| 2020-09-30 | $2.64M 10-Q · filed 2021-11-15 | $5.05M derived: sum of 2 quarters · filed 2021-11-15 | $7.22M 10-Q · filed 2021-11-15 | ||||
| 2020-06-30 | $2.41M 10-Q · filed 2021-08-12 | $4.58M 10-Q · filed 2021-08-12 | |||||
| 2020-03-31 | $2.16M 10-Q · filed 2021-05-13 | ||||||
| 2019-09-30 | $925.00K 10-Q · filed 2020-11-16 | $2.41M derived: sum of 2 quarters · filed 2020-11-16 | $2.46M 10-Q · filed 2020-11-16 | ||||
| 2019-06-30 | $1.48M 10-Q · filed 2020-08-12 | $1.53M 10-Q · filed 2020-08-12 | |||||
| 2018-09-30 | $102.00K 10-Q · filed 2019-11-18 | $267.00K 10-Q · filed 2019-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |